TransCode Therapeutics, Inc.
Zdravka Medarova has a diverse work experience that spans both the industry and academia. Zdravka is currently serving as the Chief Technology Officer and Co-Founder of TransCode Therapeutics, Inc., a position they have held since October 2021. Prior to that, they worked at Massachusetts General Hospital, where they held various roles. These roles include Associate Professor (since April 2016), Assistant Professor (from April 2010 to April 2016), Instructor (from June 2007 to March 2010), and Postdoctoral Researcher (from December 2002 to May 2007).
Zdravka Medarova pursued higher education, starting with a Bachelor's degree that they obtained between 1995 and 1998 from the University of Southern Maine. Zdravka'sfield of study during this period was Pre-Medicine. Following this, they enrolled at the University of New Hampshire and completed their Doctor of Philosophy (PhD) in Genetics between 1998 and 2002.
This person is not in any teams
This person is not in any offices
TransCode Therapeutics, Inc.
TransCode Therapeutics is an emerging RNA oncology company committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics. Our lead therapeutic candidate, that we believe has blockbuster potential, targets an RNA molecule which has been shown to be the driver of metastatic disease across multiple tumor typesand has been validated pre-clinically in our lab at MGH. Our initial FIH clinical study, for which an eIND filing is planned for Q1 of 2022, is intended to provide positive proof-of-mechanism for the TTX platform.